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ABSTRACT
Background: Although the benefits of helmet therapy for positional plagiocephaly are strongly 
correlated with age, the effective period remains controversial. However, most physicians 
agree that effective results can be obtained in patients within the age of 6 months. Owing to 
the characteristics of positional plagiocephaly in Koreans, many Korean patients have delayed 
diagnosis, and because this results in delayed onset of the helmet therapy, the outcomes 
remain largely underevaluated. In the management of late-diagnosed positional plagiocephaly, 
we aimed to determine the factors affecting the effective application of helmet therapy.
Methods: We recruited 39 consecutive patients with positional plagiocephaly who received 
helmet therapy and completed the treatment between December 2008 and June 2016. The 
ages at initiation and completion of treatment, duration of daily use, initial and final absolute 
diagonal differences, cephalic index, and cranial vault asymmetry index (CVAI) were analysed 
using data retrospectively collected from the patients' medical records.
Results: We identified 12 patients with late-diagnosed positional plagiocephaly, of whom 
83.33% were effectively treated. The effective change in CVAI (%) was affected by age at 
treatment initiation (P = 0.001), initial absolute diagonal distance differences (P < 0.001), 
and initial CVAI (P < 0.001). Up to 9 months, a gradual change of at least 1% CVAI was 
attained. Treatment initiation at ages < 5.5 months was beneficial. Even at a later age, 
patients with an initial absolute diagonal distance difference of > 13.50 mm and initial CVAI 
of > 11.03% could receive effective helmet therapy.
Conclusion: The efficacy of helmet therapy in late-diagnosed patients can be predicted on 
the basis of not only age at treatment initiation, but also initial absolute diagonal distance 
differences and initial CVAI. We anticipate that even patients with late-diagnosed positional 
plagiocephaly can expect better helmet therapy outcomes.
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INTRODUCTION
Positional plagiocephaly is a deformation of the shape of the head due to external forces, and 
is not related to premature synostotic fusion of cranial sutures. Its incidence is estimated 
at 46.6%, making it the most common positional head shape abnormality among infants.1 
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Moderate to severe cases that are left untreated predispose infants to the risk of cosmetic, 
and more importantly, psychomotor and cognitive problems.2
Helmet therapy is a commonly prescribed treatment strategy for positional plagiocephaly and 
is regarded as a low-risk intervention. The primary consideration regarding the use of helmet 
therapy is its cost. Additionally, a recent review of helmet therapy found that it is associated 
with mild complications that can be resolved by discontinuing the treatment. The morbidity 
is usually due to mild skin irritation, which emphasises the need to maintain good hygiene.3
The benefits of helmet therapy strongly correlate with age. Prior studies have advocated 
helmet therapy at a younger age to obtain maximum benefits.4-7 Likewise, several authors 
believe that the cut-off point where helmet therapy ceases to be beneficial could be as early 
as 8–12 months.5-7 Recent reports have indicated that the age at treatment initiation and the 
severity of the asymmetry are the main factors that affect the effectiveness of treatment.8 
Although physicians consider these factors as important, early-stage positional plagiocephaly 
can easily be considered as normal; thus, the patient's first clinic visit for diagnosis can be 
delayed. Moreover, in Korea, we have frequently encountered patients with deformational 
plagiocephaly who are more than 6 months old. At this point, the appropriate treatment with 
or without a helmet must be decided. No consensus has been reached regarding the effective 
period range of helmet therapy for positional plagiocephaly.
In the present study, we clarified whether delayed initiation of helmet therapy is still effective, 
and investigated the factors affecting the effective application of helmet therapy for late-
diagnosed plagiocephaly. If we extend the applicative period of effective helmet therapy, the 
results of this study can be implemented in daily practice as a practical guideline for treating 
patients with late-diagnosed positional plagiocephaly.
METHODS
Patients
In this retrospective chart review, we included 53 patients with positional plagiocephaly who 
received complete helmet therapy between December 2008 and June 2016. This study was 
conducted at an outpatient clinic in our institution. The inclusion criteria were as follows: 
patients diagnosed with positional plagiocephaly, patients with a cranial vault asymmetry 
index (CVAI) of > 10 mm, patients whose parents had good compliance in recording their 
child's helmet use time, and patients who wore the helmet for > 10 hours/day for > 8 weeks. 
The exclusion criteria were as follows: patients with craniosynostosis or other syndromic 
diseases, patients who were lost to follow-up, and patients with incomplete medical records. 
Finally, 39 patients (23 males and 16 females) were included in the study.
Therapy protocol
Helmet orthoses manufactured by a single company (Gio Inc., Seoul, Korea) were used 
in this study. In accordance with the patients' head parameters such as anteroposterior, 
bitemporal, and diagonal distances measured using a calliper, a customized helmet was 
made.9 The helmet was composed of a plastic outer shell and soft inner foam with the 
thickness depending on the patients' current measurements. Every 2–4 weeks, the cranium 
was measured, and the helmet size was adjusted accordingly. Parents were instructed to 
educate their children on the use of the helmet as much as possible, and have their children 
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wear the helmet for at least 10 hours a day. If the child could not follow this recommendation, 
the treatment was continued, but the patient was not included in the study. We defined 
the treatment end point as a CVAI difference of ≤ 3.5% or absolute CVAI difference of < 5 
mm, with consideration of the induction of prominent areas to be retained passively and 
flattened areas to grow rapidly into the hollow space in the helmet.5 After confirmation of the 
treatment end point, the helmet therapy was discontinued. However, if the total treatment 
period was > 18 months, even if the treatment end point was not attained, the treatment was 
ended owing to patient compliance.
Outcome analysis
The data recorded included age at commencement of treatment (months), age at completion 
of treatment, duration of treatment (months), daily use duration (hours), initial and final 
absolute diagonal differences (mm), and cephalic index. Diagonal distance was defined as the 
frontozygomatic-to-contralateral occipital (euryon) distance from both sides, and cephalic 
index was defined as the maximal length and breadth measured on the skull radiograph 
obtained at each period (breadth/length × 100) (Fig. 1).10 With these measurements, we 
calculated CVAI, defined as the absolute diagonal difference divided by the shorter diagonal 
distance (absolute diagonal difference/shorter diagonal distance × 100).11 We defined 
improvement rate as the difference in the CVAI values at the end and beginning of treatment, 
divided by the treatment duration. At the end of the helmet therapy, effectiveness was 
confirmed when the CVAI was ≤ 3.5%.
Statistical analysis
Statistical analysis was performed with the SPSS version 19.0 software (IBM Corporation, 
Armonk, NY, USA), with the level of significance set at P < 0.05. Variables were eligible for 
entry into the multiple logistic regression model if they were significantly associated with the 
initial measurements at a P value of < 0.25.12 For the analysis of the relative strength between 
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Fig. 1. Measuring cranial vault asymmetry index. Absolute diagonal difference is divided by shorter diagonal distances (× 100%). Diagonal A is distance from the 
FZr to the contralateral EUl and diagonal B is distance from the FZl to the contralateral EUr. (A) The severity of asymmetry is shown to be increasing from left to 
right. (B) Landmarks. 
FZr = right frontozygomatic point, EUl = left euryon point, FZl = left frontozygomatic point, EUr = right euryon point.
two factors, the Spearman rank correlation test was used. Factors with values > 0.5 were 
considered to have positive correlations, whereas those with values < −0.5 were considered 
to have negative correlations. A receiver-operating characteristic (ROC) curve analysis was 
performed, and the area under the curve (AUC) was calculated to identify the effective cut-off 
values of the validated variables that could predict the effectiveness of helmet therapy. All the 
graphs were created using MedCalc 13 (MedCalc software, Ostend, Belgium).
Ethics statement
This study conforms to the principles of the Declaration of Helsinki. The study protocol was 
approved by the Institutional Review Board (IRB) of Asan Medical Center (approval No. 2017-
0482). The need for informed consent was waived by the IRB of our hospital owing to the 
retrospective design of the study.
RESULTS
Thirty-nine patients with positional plagiocephaly were evaluated in this study. In accordance 
with our helmet therapy protocol, the therapy was considered successful in 24 patients 
(74.36%) with CVAI values of ≤ 3.5%. Twenty-seven patients were aged < 6 months, of whom 
14 attained successful treatment results. However, 12 patients were aged > 6 months, of whom 
10 attained effective treatment outcomes (Table 1). A representative case is shown in Fig. 2.
The mean ages of the patients at treatment initiation and duration of the treatment were 7.26 
months (range, 3–24 months) and 6.64 months (range, 3–32 months), respectively. The mean 
duration of daily helmet use was 19.03 hours/day (range, 10–22 hours/day). The mean initial 
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Table 1. Patient composition of the study group and their helmet treatment outcome
Variables Effective treatment,  
end CVAI < 3.5%
Ineffective treatment,  
end CVAI ≥ 3.5%
Total
No. of patients 24 (61.53) 15 (38.46) 39 (100)
No. of patients younger than 6 months 14 (51.85) 13 (48.15) 27 (100)
No. of patients older than 6 months 10 (83.33) 2 (16.67) 12 (100)
Values are presented as number (%).
CVAI = cranial vault asymmetry index.
BA
Fig. 2. Representative case of a patient aged 8 months, for the reception of helmet therapy. Eight months could 
be considered late to start helmet therapy; however, his initial absolute diagonal distance difference was 15 
mm and initial CVAI was 82.1. According to the regular treatment protocol, after 6 months of treatment, we 
could obtain a CVAI change of 4.06%. Proper indications for the helmet treatment can be effectively applied for 
patients with late-visited positional plagiocephaly. (A) Pre-treatment. (B) Six months post-treatment. 
CVAI = cranial vault asymmetry index.
CI was 89.95% (range, 76.9%–100%). The mean initial absolute diagonal distance difference 
was 14.44 mm (range, 10–24 mm), and the mean initial CVAI was 11.62% (range, 6.30%–
20.00%). The mean final CVAI value was 3.59% (range, 0.6%–7.69%). The mean difference in 
the CVAI was 8.02% ± 4.38%. In the multiple logistic regression analysis, we identified three 
variables that affected the change in CVAI (%), namely age at treatment initiation (P = 0.001), 
initial absolute diagonal distance difference (P < 0.001), and initial CVAI (P < 0.001) (Table 2).
The Spearman rank correlation test for possible factors related to age at initiation of helmet 
therapy revealed that the following six parameters showed statistically significant negative 
correlations: absolute diagonal distance difference (mm; P < 0.001), CVAI change (%; P < 
0.001), absolute diagonal distance difference change velocity (mm/day; P < 0.001), absolute 
diagonal distance difference velocity (mm/month; P < 0.001), CVAI change velocity in terms 
of days (%/day; P < 0.001), and CVAI change velocity in terms of months (%/month; P < 
0.001) (Table 3). However, CVAI correction was still attained in patients who started helmet 
therapy at a later age (Fig. 3). Regarding CVAI change velocity, patients who started treatment 
at the age of 6 months showed no peak velocity and a gradual decrease in the velocity. When 
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Table 2. Multiple logistic regression test for effective change in CVAI (%)
Variables Mean SD P value
Start age, mon 7.2564 5.00903 0.001a
Treatment duration, mon 6.6410 5.09637 0.410
Applied hr/day 19.0256 5.78331 0.451
Initial CI index 89.9538 5.74579 0.551
Initial absolute diagonal distance difference, mm 14.4359 4.08331 < 0.001a
Initial CVAI index, % 11.6156 3.60150 < 0.001a
SD = standard deviation, CVAI = cranial vault asymmetry index, CI = confidence interval.
aStatistically significant P < 0.05.
Table 3. Correlation between variables of effective helmet therapy and starting age (month), by the Spearman 
rank correlation test
Variables Spearman's 
coefficient of rank 
correlation, rho
95% CI for rho P valuea
Absolute diagonal distance difference, mm −0.520 −0.718, −0.245 < 0.001
CVAI change, % −0.522 −0.719, −0.247 < 0.001
Absolute diagonal distance difference velocity, mm/day −0.568 −0.749, −0.307 < 0.001
Absolute diagonal distance difference velocity, mm/mon −0.568 −0.749, −0.307 < 0.001
CVAI change velocity, %/day −0.451 −0.671, −0.159 < 0.001
CVAI change velocity, %/mon −0.586 −0.761, −0.332 < 0.001
CI = confidence interval, CVAI = cranial vault asymmetry index.
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Fig. 3. Relationship between CVAI (%) change and starting age of helmet treatment (month). This shows that 
patients older than 6 months can still have CVAI change (%). 
CVAI = cranial vault asymmetry index.
helmet use has a positive effect, a gradual change in CVAI of at least 1% should be apparent. 
Lower values are considered to have a minimal effect on treatment. Up to 9 months, as 
demonstrated by the velocity, the time at which a change of > 1%/month is achieved could be 
an effective period (Fig. 4).
To investigate the optimal age range when a child should commence helmet therapy for 
effective treatment, we performed ROC curve analysis of the age at treatment initiation 
with a 95% confidence interval (CI). We found that the cut-off age for effective treatment 
was 5.5 months, with 66.7% sensitivity and 66.7% specificity (AUC-ROC, 0.796; 95% CI, 
0.156–0.497; P < 0.001) (Fig. 5). The cut-off initial absolute diagonal distance difference 
for effective treatment was 13.50 mm, with 66.7% sensitivity and 66.7% specificity (AUC-
ROC, 0.679; 95% CI, 0.510–0.848; P < 0.001) (Fig. 6). The cut-off initial CVAI for effective 
treatment was 11.03%, with 66.7% sensitivity and 66.7% specificity (AUC-ROC, 0.674; 95% 
CI, 0.503–0.844; P < 0.001) (Fig. 7).
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Fig. 4. Relationship between CVAI change velocity (%/month) and starting age of helmet treatment (month). This 
shows that between 5 and 10 months, a CVAI change/month greater than 1% could be considered effective. 
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Fig. 5. Relationship between age at treatment initiation and treatment effectiveness. ROC defining the 
sensitivity and specificity of age at treatment initiation for effective helmet treatment in patients with positional 
plagiocephaly (ROC area, 0.796; 95% confidence interval, 0.156–0.497; P < 0.001). 
ROC = receiver-operating curve.
DISCUSSION
Despite the common understanding that early initiation of helmet therapy is better for 
treating positional plagiocephaly, in reality, many patients visit our clinic at a later age. Given 
the natural history of positional plagiocephaly, parents easily consider that natural skull 
remodelling can resolve positional plagiocephaly, which results in delayed clinic visit.13,14 
Particularly, Korea has a large population with brachycephaly based on the standardized 
cephalic index, but reference values for Koreans have not been established yet. Owing to 
these characteristics, cases of delayed diagnosis are common in Korea. Previous studies 
have only investigated possible factors for attaining the maximum benefit from helmet 
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Fig. 6. Relationship between initial absolute diagonal distance differences and treatment effectiveness. ROC 
defining the sensitivity and specificity of initial absolute diagonal distance differences for effective helmet treatment 
in patients with positional plagiocephaly (ROC area, 0.679; 95% confidence interval, 0.510–0.848; P < 0.001). 
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Fig. 7. Relationship between initial CVAI and treatment effectiveness. ROC defining the sensitivity and specificity 
of initial CVAI for effective helmet treatment in patients with positional plagiocephaly (ROC area, 0.674; 95% 
confidence interval, 0.503–0.844; P < 0.001). 
CVAI = cranial vault asymmetry index, ROC = receiver-operating curve.
therapy for positional plagiocephaly. The general consensus is that in patients aged 5–6 
months, repositioning therapy is preferred over helmet therapy.4 Several previous studies 
described the benefits of introducing helmet therapy at earlier ages (< 6 months), including 
higher correction rates and the resulting shorter treatment durations.4,7,15 Therefore, when 
encountering delayed-diagnosed patients because of the unavoidable characteristics of 
positional plagiocephaly, clinicians need clearer evidence to prescribe helmet therapy. In 
clinical practice, this need is increasing, and this study demonstrated the efficacy of helmet 
therapy even in older patients.
Regarding the treatment outcomes, we observed successful outcomes in 51.85% of the 
patients who received early treatment and in 83.33% of the patients who received late 
treatment (Table 1). Many cases of successful outcomes of helmet therapy for patients 
aged < 6 months have been reported; however, the mean age of the cohorts in the previous 
studies was 19.9 weeks, and that in our study was 22.8 weeks. The patients who received early 
treatment in this study were relatively older than those in Western studies. Therefore, we 
believe that these differences may have contributed to the differences in treatment outcomes. 
Furthermore, owing to the small study population that received delayed treatment, we cannot 
conclude that late treatment has more benefits. In this study, we demonstrated that even 
patients who received late treatment had satisfactory treatment outcomes.
This study clearly reflects the Korean outpatient clinical setting with respect to positional 
plagiocephaly. This is because 12 of our 39 patients received treatment at an older age, of 
whom 83.33% showed effective treatment outcomes. Moreover, besides age at treatment 
initiation, various factors can affect the final CVAI change, such as initial absolute diagonal 
distance difference and initial CVAI. Therefore, these two factors can be considered 
concurrently when deciding whether to prescribe helmet therapy for late-visiting patients. 
Although the CVAI correction rate plummeted until no further effect could be observed after 
the age of 15 months, we still found moderate to minimal changes in CVAI range from 5 to 
10 months. The decrease in the curve was not sharp but gradual. This is in accordance with 
the findings of Seruya et al.,15 who described that the declining rate of correction reflects a 
logarithmic decline in head circumference growth. Nonetheless, head growth may actually 
reach its limit at the age of 6 years, i.e., improvement can still be observed up to that age. 
Another study with the same objective showed that the rate of improvement was the same 
between older (> 12 months) and younger patients (< 3 months).6
In this study, complication rates were not compared between early- and late-onset helmet 
therapy. As we included only patients who followed the proper helmet therapy protocol, our 
patient cohort was small and the follow-up period was short. These are the limitations of our 
study. Even though we demonstrated that starting helmet therapy at later ages is possible, 
the slow improvement rate can increase the risk of complications such as dermatitis, which 
potentially outweighs the benefits. However, we did not observe any notable complications such 
as pressure sores, skin infections, or subcutaneous abscesses. Thus, we expect that our findings 
support the benefits of helmet therapy more than its risk of complications. More studies on 
the potential complications of helmet therapy are warranted. At this point, we emphasise that 
diagnosis at a later age is not a valid reason to refuse the commencement of helmet therapy. The 
effectiveness of helmet therapy depends not only on the age at treatment initiation but also on 
the initial absolute diagonal distance difference and CVAI index. Once patients are diagnosed 
with positional plagiocephaly, an initial absolute diagonal distance difference of > 13.50 mm 
and an initial CVAI index of > 11.03% can predict the effectiveness of the treatment, given that 
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the proper treatment protocol is applied, regardless of late onset of treatment. One similarity 
concerning the optimal age among the different findings is that several factors influence the 
relationship between optimal age and plagiocephaly correction rate, such as severity of the 
deformity and parent compliance.6 Several other authors asserted that the cut-off point at which 
helmet therapy ceases to be beneficial could be as early as 8–12 months.6,7
Implementing the concept of a long effective period in plagiocephaly management will help 
healthcare providers educate parents. One study reported that helmet therapy confers a lot 
of stress on parents, who are the actual caregivers. A significant proportion of caregivers 
(31.9%) temporarily stop the therapy without consulting their physicians.4 Establishment 
of an optimal treatment period would mean that parents should take full advantage of 
the period where maximum benefits can be received. Furthermore, understanding that 
the treatment can be effective even after 6 months of age can give parents psychological 
encouragement to endure the hardship from the treatment for a certain limited period.
We allowed parents to minimise the time of helmet use when the patient refuses the 
treatment, because we are more concerned about steady treatment. In the retrospective 
chart review, we had to exclude all these patients in accordance with the strictly accepted 
helmet therapy protocol; thus, the number of patients included in this study was small. Our 
future studies will focus on the differences between data of Korean patients with positional 
plagiocephaly and the standardized reference, as well as on the effect of the treatment 
protocol on a wider range of patients. One more limitation of our study was the shorter study 
period compared to those of other studies.
In conclusion, the effectiveness of helmet therapy is affected by age at treatment initiation, 
initial absolute diagonal distance difference, and initial CVAI. Age has been the only main 
consideration for indicating helmet therapy; however, late-diagnosed patients can attain 
effective treatment outcomes despite gradual decrease in the correction rate. We recommend 
that healthcare providers should not hesitate to introduce helmet therapy to patients who 
visit the clinic beyond the optimal effective period if they fulfil the treatment criteria.
REFERENCES
 1. Mawji A, Vollman AR, Fung T, Hatfield J, McNeil DA, Sauvé R. Risk factors for positional plagiocephaly 
and appropriate time frames for prevention messaging. Paediatr Child Health 2014;19(8):423-7. 
PUBMED | CROSSREF
 2. Bialocerkowski AE, Vladusic SL, Wei Ng C. Prevalence, risk factors, and natural history of positional 
plagiocephaly: a systematic review. Dev Med Child Neurol 2008;50(8):577-86. 
PUBMED | CROSSREF
 3. Gump WC, Mutchnick IS, Moriarty TM. Complications associated with molding helmet therapy for 
positional plagiocephaly: a review. Neurosurg Focus 2013;35(4):E3. 
PUBMED | CROSSREF
 4. Kluba S, Kraut W, Reinert S, Krimmel M. What is the optimal time to start helmet therapy in positional 
plagiocephaly? Plast Reconstr Surg 2011;128(2):492-8. 
PUBMED | CROSSREF
 5. Yoo HS, Rah DK, Kim YO. Outcome analysis of cranial molding therapy in nonsynostotic plagiocephaly. 
Arch Plast Surg 2012;39(4):338-44. 
PUBMED | CROSSREF
 6. Couture DE, Crantford JC, Somasundaram A, Sanger C, Argenta AE, David LR. Efficacy of passive helmet 
therapy for deformational plagiocephaly: report of 1050 cases. Neurosurg Focus 2013;35(4):E4. 
PUBMED | CROSSREF
9/10https://jkms.org https://doi.org/10.3346/jkms.2020.35.e295
Helmet Therapy for Late Positional Plagiocephaly
7. Freudlsperger C, Bodem JP, Kargus S, Castrillon-Oberndorfer G, Hoffman J, Engel M. The incidence of 
complications associated with molding helmet therapy: an avoidable risk in the treatment of positional 
head deformities? J Craniofac Surg 2015;26(4):e299-302. 
PUBMED | CROSSREF
8. Kunz F, Schweitzer T, Kunz J, Waßmuth N, Stellzig-Eisenhauer A, Böhm H, et al. Head orthosis therapy 
in positional plagiocephaly: influence of age and severity of asymmetry on effect and duration of therapy. 
Plast Reconstr Surg 2017;140(2):349-58. 
PUBMED | CROSSREF
9. Kwon DR. Sonographic analysis of changes in skull shape after cranial molding helmet therapy in infants 
with deformational plagiocephaly. J Ultrasound Med 2016;35(4):695-700. 
PUBMED | CROSSREF
 10. Heller JB, Heller MM, Knoll B, Gabbay JS, Duncan C, Persing JA. Intracranial volume and cephalic index 
outcomes for total calvarial reconstruction among nonsyndromic sagittal synostosis patients. Plast 
Reconstr Surg 2008;121(1):187-95. 
PUBMED | CROSSREF
 11. Loveday BP, de Chalain TB. Active counterpositioning or orthotic device to treat positional plagiocephaly? 
J Craniofac Surg 2001;12(4):308-13. 
PUBMED | CROSSREF
 12. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in 
exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106(2):196-204. 
PUBMED | CROSSREF
 13. Rekate HL. Occipital plagiocephaly: a critical review of the literature. J Neurosurg 1998;89(1):24-30. 
PUBMED | CROSSREF
 14. Pomatto JK, Littlefield TR, Manwaring K, Beals SP. Etiology of positional plagiocephaly in triplets 
and treatment using a dynamic orthotic cranioplasty device. Report of three cases. Neurosurg Focus 
1997;2(2):e2. 
PUBMED | CROSSREF
 15. Seruya M, Oh AK, Taylor JH, Sauerhammer TM, Rogers GF. Helmet treatment of deformational 




Helmet Therapy for Late Positional Plagiocephaly
